DFCM
BTAI icon

Dark Forest Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Dark Forest Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Hold
0
– -$37 – 1068
2023
Q1 		– Hold
0
– – – 1136
2022
Q4 		– Hold
0
– – – 1068
2022
Q1 		– Sell
-2
Closed – – 1309
2021
Q4 		$0 Buy
+2
New +$858 ﹤0.01% 1448

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dark Forest Capital Management's BTAI Position: Q2 2023 in Review

Dark Forest Capital Management held its BioXcel Therapeutics (BTAI) position steady in Q2 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1068.

Dark Forest Capital Management first reported a position in BTAI in Q4 2021 and has held it in 1 quarter since. The position peaked at $0 in Q4 2021. 88 funds tracked by Wall St. Rank hold BTAI as of Q2 2023.

  • Dark Forest Capital Management held 0 shares of BioXcel Therapeutics worth $0 as of Q2 2023.
  • Dark Forest Capital Management left its BioXcel Therapeutics share count unchanged in Q2 2023.
  • BioXcel Therapeutics made up ﹤0.01% of Dark Forest Capital Management's portfolio in Q2 2023, its #1068 holding.
  • Dark Forest Capital Management first reported a position in BioXcel Therapeutics in Q4 2021 and has held it in 1 quarter since.
  • Dark Forest Capital Management's BioXcel Therapeutics position peaked at $0 in Q4 2021.
  • 88 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2023.

Based on Dark Forest Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.